Business Description
Alzamend Neuro Inc
NAICS : 541714
SIC : 2833
ISIN : US02262M4078
Share Class Description:
FRA:9ZT1: Ordinary SharesDescription
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.6 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -156.3 | |||||
| 3-Year EPS without NRI Growth Rate | -153.5 | |||||
| 3-Year FCF Growth Rate | -195.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 73.01 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -56.5 | |||||
| 12-1 Month Momentum % | -74.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | |||||
| Quick Ratio | 3.8 | |||||
| Cash Ratio | 3.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -322.24 | |||||
| ROIC % | -2137.1 | |||||
| ROC (Joel Greenblatt) % | -2744.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.77 | |||||
| Price-to-Tangible-Book | 1.77 | |||||
| EV-to-EBIT | -1.17 | |||||
| EV-to-Forward-EBIT | -1.58 | |||||
| EV-to-EBITDA | -1.18 | |||||
| EV-to-Forward-EBITDA | -0.33 | |||||
| EV-to-FCF | -0.85 | |||||
| Price-to-Net-Current-Asset-Value | 1.89 | |||||
| Price-to-Net-Cash | 2.35 | |||||
| Earnings Yield (Greenblatt) % | -85.47 | |||||
| FCF Yield % | -116.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alzamend Neuro Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 69.15 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 2.16 | ||
| 12-1 Month Momentum % | -74.44 | ||
| 52-Week Range (€) | 2.159999 - 10.919999 | ||
| Shares Outstanding (Mil) | 6.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alzamend Neuro Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alzamend Neuro Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alzamend Neuro Inc Frequently Asked Questions
What is Alzamend Neuro Inc(FRA:9ZT1)'s stock price today?
The current price of FRA:9ZT1 is €2.16. The 52 week high of FRA:9ZT1 is €10.92 and 52 week low is €2.16.
When is next earnings date of Alzamend Neuro Inc(FRA:9ZT1)?
The next earnings date of Alzamend Neuro Inc(FRA:9ZT1) is 2025-03-25 Est..
Does Alzamend Neuro Inc(FRA:9ZT1) pay dividends? If so, how much?
Alzamend Neuro Inc(FRA:9ZT1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers